Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Asthma & Chronic Obstructive Pulmonary Disorder | Emerging Therapies | Salmeterol/Fluticasone Generic | US | Wave 1 | 2019
Mylan’s salmeterol/fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling therapies for asthma and COPD. Although other…
Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 3 | 2019
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication…
Rheumatoid Arthritis | Emerging Therapies | Olumiant (baricitinib) | US | Wave 2 | 2019
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…
Migraine | Emerging Therapies | Migraine Prophylaxis | Emgality and Ajovy | US | Wave 1 | 2018
Market Outlook The migraine prophylaxis market stands poised for disruption following the launch of three anti-CGRP monoclonal antibodies (MAbs) in the United States in 2018, with a fourth to…
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Emerging Therapies – Chimeric Antigen (CAR) T-Cell Therapy – Special Topics – US (Wave 3)
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
Ulcerative Colitis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 1 | 2018
Market Outlook Pfizer’s Xeljanz is the fist-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States, and the first targeted oral therapy to launch for the moderate to…
